MaxCyte, Inc.
MXCT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.23 | 0.00 | 1.13 |
| FCF Yield | -4.62% | -4.50% | -5.21% | -1.83% |
| EV / EBITDA | -14.97 | -18.19 | -25.84 | -37.50 |
| Quality | ||||
| ROIC | -5.32% | -6.79% | -5.63% | -5.75% |
| Gross Margin | 92.44% | 82.14% | 85.59% | 73.76% |
| Cash Conversion Ratio | 0.60 | 0.80 | 1.40 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.28% | -4.22% | -2.98% | -4.44% |
| Free Cash Flow Growth | 25.66% | 30.72% | -89.06% | -66.10% |
| Safety | ||||
| Net Debt / EBITDA | -0.45 | -0.25 | 0.41 | 0.87 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.07 | 0.19 | 0.18 | 0.26 |
| Cash Conversion Cycle | 1,212.66 | 459.20 | 408.28 | 346.61 |